Rachel Humphrey
SVP, Chief Medical Officer at CytomX Therapeutics | Boston, Massachusetts, United States
Rachel Humphrey’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Independent Board Director at Xilio Therapeutics, Inc. in July 2026 - July 2026
Chief Medical Officer at Black Diamond Therapeutics in July 2026 - July 2026
Board Director and Chief Medical Officer at Treadwell Therapeutics, Inc. in July 2026 - July 2026
Head Of Research And Development at TIO Bioventures in July 2026 - July 2026
SVP, Chief Medical Officer at CytomX Therapeutics in July 2026 - July 2026
Member Board of Directors at CytomX Therapeutics in July 2026 - July 2026
Vice President, Head of Immuno-Oncology at Eli Lilly and Company in July 2026 - July 2026
SVP, Head of Immuno-Oncology at AstraZeneca in July 2026 - July 2026
Chief Medical Officer at Mirati Therapeutics Inc in July 2026 - July 2026
Vice President, Development Lead, Immuno-oncology at Bristol-Myers Squibb in July 2026 - July 2026
Executive Director, Global Research and Development at Bristol-Myers Squibb in July 2026 - July 2026
Director, Global Clinical Leader, R & D at Bayer Pharmaceuticals in July 1997 - July 2026
Scientific Advisory Board Member at HotSpot Therapeutics, Inc. in July 2026 - Present
Scientific Advisory Board Member at Grey Wolf Therapeutics in July 2026 - Present
Independent Board Director at Sporos Bioventures in July 2026 - Present
Independent Board Director at Pyxis Oncology in July 2026 - Present
President and Founding CEO at Normunity in July 2026 - Present
The Johns Hopkins University School of Medicine, Residency, January 1989 to January 1992
Case Western Reserve University School of Medicine, MD, January 1985 to January 1989
Harvard University, BA, January 1979 to January 1983
Xilio is a Waltham, Massachusetts-based clinical-stage biopharmaceutical company focused on defeating cancer. The company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.
Discover more about CytomX Therapeutics
Director, Biologics Drug Design at Fable Therapeutics
Director, Protein Engineering at Kisbee Therapeutics
(July 2026 – July 2026)
Vice President, Corporate Communications, Investor Relations & Patient Advocacy
Vice President, Head of Investor Relations & Corporate Communications at Xilio Therapeutics, Inc.
(July 2026 – July 2026)
President and CEO at Xilio Therapeutics
Director at pRxcision
(Apr 2024 – Present)
Senior Vice President, Clinical Development at Xilio
Senior Vice President, Clinical Development at Xilio Therapeutics, Inc.
(Sep 2024 – Present)
SVP, Corporate Development and Program Leadership @ Xilio Therapeutics
Senior Vice President, Corporate Development and Program Leadership at Xilio Therapeutics, Inc.
(Jun 2024 – Present)
Medical Affairs and Clinical Development Leader
Vice President Clinical Science and Pharmacovigilance at Xilio Therapeutics, Inc.
(Dec 2023 – Present)
What is Rachel W Humphrey email address?
Email Rachel W Humphrey at [email protected], [email protected] and [email protected]. This email is the most updated Rachel W Humphrey's email found in 2026.
What is Rachel W Humphrey phone number?
Rachel W Humphrey phone number is 2034352152.
How to contact Rachel W Humphrey?
To contact Rachel W Humphrey send an email to [email protected], [email protected] or [email protected]. If you want to call Rachel W Humphrey try calling on 2034352152.
What company does Rachel Humphrey work for?
Rachel Humphrey works for CytomX Therapeutics.
What is Rachel Humphrey's role at CytomX Therapeutics?
Rachel Humphrey is SVP, Chief Medical Officer
What industry does Rachel Humphrey work in?
Rachel Humphrey works in the Pharmaceuticals industry.
